PMID- 26477621
OWN - NLM
STAT- MEDLINE
DCOM- 20161014
LR  - 20191113
IS  - 2212-3946 (Electronic)
IS  - 1574-888X (Linking)
VI  - 11
IP  - 2
DP  - 2016
TI  - Advances in Stem Cell Therapy for Leukemia.
PG  - 158-65
AB  - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most 
      effective post remission treatment for leukemia, resulting in lower relapse rates 
      than alternative therapies. However, it is limited by the lack of suitable human 
      leukocyte antigen (HLA) matched donors and high rates of transplant-related 
      morbidity and mortality. Cord blood transplantation (CBT) and haploidentical SCT 
      (haplo-SCT) expand the potential donor pool but are also associated with major 
      complications. Co-infusion of third-party donor stem cells with a CBT/haplo-SCT, 
      which is called "dual transplantation," has been reported to improve the outcome 
      of HSCT by accelerating hematopoietic reconstitution and reducing the incidence 
      of graft-versus-host disease (GVHD). In addition, infusion of HLA-mismatched 
      donor granulocyte colony-stimulating factor-mobilized donor peripheral blood stem 
      cells after chemotherapy, the so called "microtransplantation", has been shown to 
      promote the graft-versus-leukemia effect and hasten hematopoietic recovery 
      without amplifying GVHD. Herein, we review recent advances in stem cell therapy 
      for leukemia with a specific focus on dual transplantation and 
      microtransplantation.
FAU - Tian, Hong
AU  - Tian H
FAU - Qu, Qi
AU  - Qu Q
FAU - Liu, Liming
AU  - Liu L
FAU - Wu, Depei
AU  - Wu D
AD  - Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow 
      University, Collaborative Innovation Center of Hematology, Soochow University, 
      Suzhou Institute of Blood and Marrow Transplantation, 188 Shizi Street, Suzhou 
      215006, China. wudepei@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Stem Cell Res Ther
JT  - Current stem cell research & therapy
JID - 101272517
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Cell- and Tissue-Based Therapy
MH  - *Cord Blood Stem Cell Transplantation
MH  - Graft vs Host Disease/etiology/pathology
MH  - HLA Antigens/immunology
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Leukemia/pathology/*therapy
MH  - Transplantation, Homologous
EDAT- 2015/10/20 06:00
MHDA- 2016/10/16 06:00
CRDT- 2015/10/20 06:00
PHST- 2015/06/29 00:00 [received]
PHST- 2015/10/16 00:00 [accepted]
PHST- 2015/10/20 06:00 [entrez]
PHST- 2015/10/20 06:00 [pubmed]
PHST- 2016/10/16 06:00 [medline]
AID - CSCRT-EPUB-71167 [pii]
AID - 10.2174/1574888x10666151019120217 [doi]
PST - ppublish
SO  - Curr Stem Cell Res Ther. 2016;11(2):158-65. doi: 
      10.2174/1574888x10666151019120217.